Neopharmed Gentili S.p.A. (Irish affiliate) / BioCryst Pharmaceuticals, Inc.
2026 · Licensing/Option · $345M · Complete
Announcement Sentiment
50
Neutral / mixed
BioCryst granted an Irish affiliate of Neopharmed Gentili exclusive rights to commercialize navenibart for hereditary angioedema in Europe. BioCryst receives $70M upfront, up to $275M in regulatory and sales milestones, and tiered royalties of 18% to 30% on net sales. Builds on the prior 2025 sale of BioCryst's European ORLADEYO business to Neopharmed Gentili.